Jump to content

Stereochemistry

From Wikipedia, the free encyclopedia
(Redirected from Stereochemical)
The different types of isomers. Stereochemistry focuses on stereoisomers.

Stereochemistry, a subdiscipline of chemistry, studies the spatial arrangement of atoms that forms the structure of molecules and their manipulation.[1] The study of stereochemistry focuses on the relationships between stereoisomers, which by definition have the same molecular formula and sequence of bonded atoms (constitution), but differ in the geometric positioning of the atoms in space. For this reason, it is also known as 3D chemistry—the prefix "stereo-" means "three-dimensionality".[2]

Stereochemistry spans the entire spectrum of organic, inorganic, biological, physical and especially supramolecular chemistry. Stereochemistry includes methods for determining and describing these relationships; the effect on the physical or biological properties these relationships impart upon the molecules in question, and the manner in which these relationships influence the reactivity of the molecules in question (dynamic stereochemistry).

History

[edit]

It was not until after the observations of certain molecular phenomena that stereochemical principles were developed. In 1815, Jean-Baptiste Biot's observation of optical activity marked the beginning of organic stereochemistry history. He observed that organic molecules were able to rotate the plane of polarized light in a solution or in the gaseous phase.[3] Despite Biot's discoveries, Louis Pasteur is commonly described as the first stereochemist, having observed in 1842 that salts of tartaric acid collected from wine production vessels could rotate the plane of polarized light, but that salts from other sources did not. This was the only physical property that differed between the two types of tartrate salts, which is due to optical isomerism. In 1874, Jacobus Henricus van 't Hoff and Joseph Le Bel explained optical activity in terms of the tetrahedral arrangement of the atoms bound to carbon. Kekulé used tetrahedral models earlier in 1862 but never published these; Emanuele Paternò probably knew of these but was the first to draw and discuss three dimensional structures, such as of 1,2-dibromoethane in the Giornale di Scienze Naturali ed Economiche in 1869.[4] The term "chiral" was introduced by Lord Kelvin in 1904. Arthur Robertson Cushny, Scottish Pharmacologist, in 1908, first offered a definite example of a bioactivity difference between enantiomers of a chiral molecule viz. (-)-Adrenaline is two times more potent than the (±)- form as a vasoconstrictor and in 1926 laid the foundation for chiral pharmacology/stereo-pharmacology[5][6] (biological relations of optically isomeric substances). Later in 1966, the Cahn-Ingold-Prelog nomenclature or Sequence rule was devised to assign absolute configuration to stereogenic/chiral center (R- and S- notation) [7] and extended to be applied across olefinic bonds (E- and Z- notation).

Significance

[edit]

Cahn–Ingold–Prelog priority rules are part of a system for describing a molecule's stereochemistry. They rank the atoms around a stereocenter in a standard way, allowing the relative position of these atoms in the molecule to be described unambiguously. A Fischer projection is a simplified way to depict the stereochemistry around a stereocenter.

Thalidomide example

[edit]
Thalidomide structures

Stereochemistry has important applications in the field of medicine, particularly pharmaceuticals. An often cited example of the importance of stereochemistry relates to the thalidomide disaster. Thalidomide is a pharmaceutical drug, first prepared in 1957 in Germany, prescribed for treating morning sickness in pregnant women. The drug was discovered to be teratogenic, causing serious genetic damage to early embryonic growth and development, leading to limb deformation in babies. Some of the several proposed mechanisms of teratogenicity involve a different biological function for the (R)- and the (S)-thalidomide enantiomers.[8] In the human body however, thalidomide undergoes racemization: even if only one of the two enantiomers is administered as a drug, the other enantiomer is produced as a result of metabolism.[9] Accordingly, it is incorrect to state that one stereoisomer is safe while the other is teratogenic.[10] Thalidomide is currently used for the treatment of other diseases, notably cancer and leprosy. Strict regulations and controls have been implemented to avoid its use by pregnant women and prevent developmental deformations. This disaster was a driving force behind requiring strict testing of drugs before making them available to the public.

Definitions

[edit]
Further information: Torsion angle
syn/anti peri/clinal
syn/anti peri/clinal

Many definitions that describe a specific conformer (IUPAC Gold Book) exist, developed by William Klyne and Vladimir Prelog, constituting their Klyne–Prelog system of nomenclature:

  • a torsion angle of ±60° is called gauche[11]
  • a torsion angle between 0° and ±90° is called syn (s)
  • a torsion angle between ±90° and 180° is called anti (a)
  • a torsion angle between 30° and 150° or between –30° and –150° is called clinal
  • a torsion angle between 0° and 30° or 150° and 180° is called periplanar (p)
  • a torsion angle between 0° to 30° is called synperiplanar or syn- or cis-conformation (sp)
  • a torsion angle between 30° to 90° and –30° to –90° is called synclinal or gauche or skew (sc)[12]
  • a torsion angle between 90° to 150°, and –90° to –150° is called anticlinal (ac)
  • a torsion angle between ±150° to 180° is called antiperiplanar or anti or trans (ap).

Torsional strain results from resistance to twisting about a bond.

Types

[edit]
  • Atropisomerism
    An energetic form of axial chirality. This form of chirality derives from differential substitution about a bond, commonly between two sp²-hybridized atoms.[13]
  • Cis–trans isomerism
    Also referred to as geometric isomers, these compounds have different configurations due to the inflexible structure of the molecule. Two requirements must be met for a molecule to present cis-trans isomerism:[14]
    1. Rotation within the molecule must be restricted.
    2. Two nonidentical groups must be on each doubly bonded carbon atom.
  • Conformational isomerism
    This form of isomerism is also referred to as conformers, rotational isomers, and rotamers. Conformational isomerism is produced by rotation about the Single bond.
  • Diastereomers
    These stereoisomers are non-image, non-identical. Diastereomers occur when the stereoisomers of a compound have differing configurations at corresponding stereocenters.[15]
  • Enantiomers
    Stereoisomers which are nonsuperposable, mirror images.[16]

See also

[edit]
Wikiquote has quotations related to Stereochemistry.

References

[edit]
  1. ^ Ernest Eliel Basic Organic Stereochemistry ,2001 ISBN 0471374997; Bernard Testa and John Caldwell Organic Stereochemistry: Guiding Principles and Biomedicinal Relevance 2014 ISBN 3906390691; Hua-Jie Zhu Organic Stereochemistry: Experimental and Computational Methods 2015 ISBN 3527338225; László Poppe, Mihály Nógrádi, József Nagy, Gábor Hornyánszky, Zoltán Boros Stereochemistry and Stereoselective Synthesis: An Introduction 2016 ISBN 3527339019
  2. ^ "the definition of stereo-". Dictionary.com. Archived from the original on 2010-06-09.
  3. ^ Nasipuri, D (2021). Stereochemistry of Organic Compounds Principles and Applications (4th ed.). New Delhi: New Age International. p. 1. ISBN 978-93-89802-47-4.
  4. ^ Paternò, Emanuele (1869). "Intorno all'azione del percloruro di fosforo sul clorale". Giorn. Sci. Nat. Econ. 5: 117–122.
  5. ^ Smith, Silas W. (2009-05-04). "Chiral Toxicology: It's the Same Thing…Only Different". Toxicological Sciences. 110 (1): 4–30. doi:10.1093/toxsci/kfp097. ISSN 1096-6080. PMID 19414517.
  6. ^ Patočka, Jiří; Dvořák, Aleš (2004-07-31). "Biomedical aspects of chiral molecules". Journal of Applied Biomedicine. 2 (2): 95–100. doi:10.32725/jab.2004.011.
  7. ^ Cahn, R. S.; Ingold, Christopher; Prelog, V. (April 1966). "Specification of Molecular Chirality". Angewandte Chemie International Edition in English. 5 (4): 385–415. doi:10.1002/anie.196603851. ISSN 0570-0833.
  8. ^ Stephens TD, Bunde CJ, Fillmore BJ (June 2000). "Mechanism of action in thalidomide teratogenesis". Biochemical Pharmacology. 59 (12): 1489–99. doi:10.1016/S0006-2952(99)00388-3. PMID 10799645.
  9. ^ Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL (2004). "Clinical pharmacokinetics of thalidomide". Clin. Pharmacokinet. 43 (5): 311–327. doi:10.2165/00003088-200443050-00004. PMID 15080764. S2CID 37728304.
  10. ^ Francl, Michelle (2010). "Urban legends of chemistry". Nature Chemistry. 2 (8): 600–601. Bibcode:2010NatCh...2..600F. doi:10.1038/nchem.750. PMID 20651711.
  11. ^ Anslyn, Eric V. and Dougherty, Dennis A. Modern Physical Organic Chemistry. University Science (2005), 1083 pp. ISBN 1-891389-31-9
  12. ^ IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold Book") (1997). Online corrected version: (2006–) "gauche". doi:10.1351/goldbook.G02593
  13. ^ Toenjes, Sean T; Gustafson, Jeffrey L (February 2018). "Atropisomerism in medicinal chemistry: challenges and opportunities". Future Medicinal Chemistry. 10 (4): 409–422. doi:10.4155/fmc-2017-0152. ISSN 1756-8919. PMC 5967358. PMID 29380622.
  14. ^ "13.2: Cis-Trans Isomers (Geometric Isomers)". Chemistry LibreTexts. 2014-07-17. Retrieved 2022-11-27.
  15. ^ Garrett, Reginald H.; Grisham, Charles M. (2005). Biochemistry (3rd ed.). Belmont, CA: Thomson Brooks/Cole. ISBN 0-534-49033-6. OCLC 56058171.
  16. ^ Caillet, Céline; Chauvelot-Moachon, Laurence; Montastruc, Jean-Louis; Bagheri, Haleh; French Association of Regional Pharmacovigilance Centers (November 2012). "Safety profile of enantiomers vs . racemic mixtures: it's the same?: Short report". British Journal of Clinical Pharmacology. 74 (5): 886–889. doi:10.1111/j.1365-2125.2012.04262.x. PMC 3495153. PMID 22404187.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Stereochemistry&oldid=1255146728"